Skip to main content
AAN.com

Abstract

Objective: B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relapsing MS with breakthrough disease defined by clinical and MRI activity (Class III evidence).
Methods: Thirty subjects with a relapse within the past 18 months despite use of an injectable disease-modifying agent, and with at least 1 gadolinium-enhancing (GdE) lesion on any of 3 pretreatment MRIs, received rituximab administered at 375 mg/m2 weekly × 4 doses. Three monthly posttreatment brain MRI scans were obtained beginning 12 weeks after the first infusion. Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) were obtained at baseline and throughout the posttreatment follow-up.
Results: GdE lesions were reduced after treatment with rituximab, with 74% of posttreatment MRI scans being free of GdE activity compared with 26% free of GdE activity at baseline (p < 0.0001). Median GdE lesions were reduced from 1.0 to 0, and mean number was reduced from 2.81 per month to 0.33 after treatment (88% reduction). MSFC improved as well (p = 0.02). EDSS remained stable.
Conclusion: Rituximab add-on therapy was effective based upon blinded radiologic endpoints in this phase II study. In combination with standard injectable therapies, rituximab was well-tolerated with no serious adverse events. B-cell–modulating therapy remains a potential option for treatment of patients with relapsing MS with an inadequate response to standard injectable therapies.
Classification of evidence: This study provides Class III evidence that add-on rituximab reduces gadolinium-enhancing brain lesions in multiple sclerosis.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Rinker JR II, Naismith RT, Cross AH. Multiple sclerosis: an autoimmune disease of the central nervous system? In: Cook SD, ed. Handbook of Multiple Sclerosis, 4th ed. New York: Taylor & Francis; 2006:95–112.
2.
Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001;112:1–14.
3.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–445.
4.
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
5.
Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–2581.
6.
Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395–400.
7.
Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
8.
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.&rdquo; Ann Neurol 2005;58:840–846.
9.
Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force. Ann Neurol 1996;39:6–16.
10.
Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961–967.
11.
Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148–157.
12.
Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389–400.
13.
Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36 suppl:S86–S90.
14.
Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain 1998;121:2011–2020.
15.
Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 2008;70:1092–1097.
16.
Bagnato F, Tancredi A, Richert N, et al. Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study. Mult Scler 2000;6:43–49.
17.
Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis: European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290–297.
18.
Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001;58:2044–2045.
19.
Paty DW, Noseworthy JH, Ebers GC. Diagnosis of multiple sclerosis. In: Paty DW, Ebers GC, eds. Multiple Sclerosis. Philadelphia: F.A. Davis; 1998:48–134.
20.
Olsson JE, Link H. Immunoglobulin abnormalities in multiple sclerosis: relation to clinical parameters: exacerbations and remissions. Arch Neurol 1973;28:392–399.
21.
Esiri MM. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977;2:478.
22.
Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981;10:149–158.
23.
Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409–421.
24.
Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363–372.
25.
Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969–4973.
26.
Constant SL. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J Immunol 1999;162:5695–5703.
27.
Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes: I: role of surface immunoglobulin receptors. J Exp Med 1984;160:1102–1113.
28.
Piccio L, Naismith RT, Trinkaus K, et al. Changes in B and T lymphocytes and chemokines with rituximab treatment in multiple sclerosis. Arch Neurol (in press 2010).
29.
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
30.
Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180:63–70.

Information & Authors

Information

Published In

Neurology®
Volume 74Number 23June 8, 2010
Pages: 1860-1867
PubMed: 20530322

Publication History

Published online: June 7, 2010
Published in print: June 8, 2010

Permissions

Request permissions for this article.

Notes

Authors

Affiliations & Disclosures

R.T. Naismith, MD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
L. Piccio, MD, PhD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
J.A. Lyons, PhD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
J. Lauber, RN
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
N.T. Tutlam, MPH
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
B.J. Parks, MD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
K. Trinkaus, PhD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
S.K. Song, PhD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.
A.H. Cross, MD
From the Departments of Neurology (R.T.N., L.P., J.L., N.T.T., B.J.P., A.H.C.), Biostatistics (K.T.), and Radiology (S.K.S.), Washington University, St. Louis, MO; and Department of Health Sciences (J.A.L.), University of Wisconsin, Milwaukee, WI.

Notes

Address correspondence and reprint requests to Dr. Robert T. Naismith, Neurology, Box 8111, 660 S. Euclid Ave., St. Louis, MO 63110 [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab, Meditsinskiy sovet = Medical Council, 12, (108-112), (2024).https://doi.org/10.21518/ms2024-318
    Crossref
  2. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines, Multiple Sclerosis and Related Disorders, 83, (105435), (2024).https://doi.org/10.1016/j.msard.2024.105435
    Crossref
  3. The Effect of Rituximab on the Cognitive Function of Patients with Relapsing-Remitting Multiple Sclerosis, Clinical Therapeutics, 46, 10, (e1-e5), (2024).https://doi.org/10.1016/j.clinthera.2024.07.011
    Crossref
  4. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1060696
    Crossref
  5. Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab, Basic & Clinical Pharmacology & Toxicology, 133, 5, (550-564), (2023).https://doi.org/10.1111/bcpt.13932
    Crossref
  6. A safety review of current monoclonal antibodies used to treat multiple sclerosis, Expert Opinion on Drug Safety, 22, 11, (1011-1024), (2023).https://doi.org/10.1080/14740338.2023.2224556
    Crossref
  7. Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis, Nature Reviews Neurology, 19, 8, (461-476), (2023).https://doi.org/10.1038/s41582-023-00838-7
    Crossref
  8. Current evidence of rituximab in the treatment of multiple sclerosis, Multiple Sclerosis and Related Disorders, 75, (104729), (2023).https://doi.org/10.1016/j.msard.2023.104729
    Crossref
  9. Monoclonal antibodies in multiple sclerosis treatment, Translational Neuroimmunology, Volume 8, (191-207), (2023).https://doi.org/10.1016/B978-0-443-18578-6.00011-8
    Crossref
  10. Efficacy and safety of rituximab in multiple sclerosis: a systematic review and meta-analysis, Acta Neurologica Belgica, 123, 6, (2115-2127), (2023).https://doi.org/10.1007/s13760-023-02329-4
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share